ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks (Q39052365)

8 September 2017

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks (English)

1 reference

8 September 2017

Eli M Roth

1

1 reference

PubMed ID

25606700

8 September 2017

James M McKenney

series ordinal

2

1 reference

8 September 2017

1 January 2015

1 reference

8 September 2017

1 reference

8 September 2017

11

1 reference

8 September 2017

1

1 reference

8 September 2017

27-37

1 reference

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

8 September 2017

1 reference

2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult

21 January 2018

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

21 January 2018

1 reference

Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.

21 January 2018

1 reference

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

21 January 2018

1 reference

Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study

21 January 2018

1 reference

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

21 January 2018

1 reference

Potential of proprotein convertase subtilisin/kexin type 9 based therapeutics

21 January 2018

1 reference

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

21 January 2018

1 reference

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody

21 January 2018

1 reference

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

21 January 2018

1 reference

Ezetimibe: cholesterol lowering and beyond

21 January 2018

1 reference

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

21 January 2018

1 reference

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FCA.14.82

1 reference

8 September 2017

1 reference

PubMed ID

25606700